Q-omics provides the consensus-scored RPL6P9 profile across patient tissues and cancer cell-line models. RPL6P9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL6P9 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RPL6P9 RNA expression shows 7,335 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where RPL6P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL6P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL6P9 survival associations across molecular data types. RPL6P9 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL6P9 RNA expression–survival associations across cancer types. High RPL6P9 expression shows unfavorable associations in KIRC, CHOL, ACC and THCA, but favorable associations in UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL6P9 RNA expression.
This table summarizes RPL6P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL6P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL6P9 shows lower tumor expression in THCA, KICH, LUSC and BLCA. The THCA box plot shows higher RPL6P9 RNA expression in normal versus tumor tissue (log2 FC = −0.125, t-test p < 0.001).
This table shows molecular features associated with RPL6P9 in patient tissues and cancer cell lines. In patient samples, RPL6P9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
